Axim Biotechnologies Inc (OTCMKTS:AXIM) Stock Continues to Trend Lower After The Recent News
Axim Biotechnologies Inc (OTCMKTS:AXIM) stock continues to trend lower extending its monthly fall. The stock has lost 15% over the past month.
Market Action
In the previous trading session, AXIM stock fell 0.40% at $0.5279. A total of 117k shares traded for the session hands, below its average volume of 114K shares. The stock opened at $0.5276 and moved in a range of $0.5200 – 0.5300.
Key Trigger
AXIM® Biotechnologies Appoints Senior DED Expert Dr. Laura Periman to its Medical Advisory Board
announce that the Company plans to develop and launch a global registry for the identification and long term management of current and former boxers with mTBI and PTSD in partnership with the World Boxing Association.
The World Boxing Association (the “WBA”), formerly known as the National Boxing Association (“NBA”), is the oldest of the four major organizations which sanction professional boxing bouts. Led by its longest serving President, Gilberto Jesus Mendoza, the WBA is committed to identifying and implementing more effective management and treatment of mild traumatic brain injury (“mTBI”).
President Mendoza stated, “It is no secret that a boxing match is highlighted by skillful defense and aggressive, sometimes violent offensive attacks. From the beginning the WBA has known that a number of our members suffer from the short and long-term effects of varying degrees of mild traumatic brain injury associated with their time competing in the ring. We believe in the promise of the resurgence of psychedelic medicine and are proud to be collaborating with Lobe as we work together to improve the lives and health of members of the WBA family.”
Trader Notes:
AXIM stock is trading below all the key moving averages with 200-day and 50-Day SMA stand at $0.67 and $0.64 respectively. The stock has jumped 22% so far this year.
